Piramal’s Sensipar Generic Blocked In US, For Now

Piramal halted sales of its generic version of Amgen’s Sensipar following a US court order that also required Amgen to furnish a $39m bond. The Sensipar generic launch landscape continues to be complex with multiple legal challenges, including those from Cipla and Sun at various stages.

Labyrinth
MULTIPLE CHALLENGES DOT THE SENSIPAR GENERIC LAUNCH LANDSCAPE

The start-stop scenario surrounding generic competition for Amgen Inc.’s Sensipar (cinacalcet) in the US continues with Piramal Enterprises Ltd. required to halt sales of its generic version of the calcium-sensing receptor agonist, at least for now.

The US District Court for the District of Delaware, acting on Amgen’s emergency motion for an injunction pending appeal, has...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

More from Business